Celgene Competitors and Similar CompaniesClear all
Celgene's competitors and similar companies include Sanofi, Idorsia, Amgen, Gilead Sciences and Regeneron Pharmaceuticals.
 Celgene Celgene is a biopharmaceutical company developing therapies for the treatment of cancer and inflammatory diseases. |  Sanofi Sanofi is a healthcare company engaged in the research, development, manufacture, and marketing of therapeutic solutions. |  Idorsia Idorsia, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs. |  Amgen Amgen (formerly known as Applied Molecular Genetics) is a biotechnology company that discovers, develops, manufactures, and delivers human therapeutics. |  Gilead Sciences Gilead Sciences is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of medicines. |  Regeneron Pharmaceuticals Regeneron Pharmaceuticals is a biopharmaceutical company that develops, manufactures, and markets medicines. | |
Founding Date | Founding Date 1986 | Founding Date 1994 | Founding Date 2017 | Founding Date 1980 | Founding Date 1987 | Founding Date 1988 |
Type | Type Subsidiary | Type Public | Type Public | Type Public | Type Public | Type Public |
Tags | ||||||
Locations | Locations Summit, US HQ Singapore, SG Boudry, CH | Locations Paris, FR HQ Hydra, DZ Buenos Aires, AR Macquarie Park, AU Melbourne, AU Virginia, AU Wien, AT see more | Locations Allschwil, CH HQ Shanghai, CN Lörrach, DE Chiyoda City, JP | Locations Thousand Oaks, US HQ Hydra, DZ Vicente López, AR Sydney, AU Wien, AT Diegem, BE Santo Amaro, BR see more | Locations Foster City, US HQ Buenos Aires, AR Melbourne, AU Wien, AT Machelen, BE São Paulo, BR Edmonton, CA see more | Locations Tarrytown, US HQ Mississauga, CA Courbevoie, FR München, DE Bengaluru, IN Dublin, IE Limerick, IE see more |
Employees | Employees 8,85219% increase | Employees 82,878 | Employees 8007% increase | Employees 25,200 | Employees 18,0006% increase | Employees 15,1068% increase |
Valuation ($) | Valuation ($) N/A | Valuation ($) 141.1 b | Valuation ($) N/A | Valuation ($) 170.4 b | Valuation ($) 110.5 b | Valuation ($) 102.2 b |
Financial | ||||||
Revenue (est.) | Revenue (est.) $15.3b (FY, 2018) | Revenue (est.) €45.4b (FY, 2025) | Revenue (est.) CHF220.6m (FY, 2025) | Revenue (est.) $36.8b (FY, 2025) | Revenue (est.) $29.4b (FY, 2025) | Revenue (est.) $14.3b (FY, 2025) |
Cost of goods | Cost of goods $587m (FY, 2018) | Cost of goods €11.6b (FY, 2025) | Cost of goods CHF20.9m (FY, 2025) | Cost of goods $12b (FY, 2025) | Cost of goods $6.2b (FY, 2025) | Cost of goods N/A |
Gross profit | Gross profit $14.7b (FY, 2018) | Gross profit €37.6b (FY, 2025) | Gross profit CHF214.3m (FY, 2025) | Gross profit $24.7b (FY, 2025) | Gross profit $23.2b (FY, 2025) | Gross profit N/A |
Net income | Net income $4b (FY, 2018) | Net income €8b (FY, 2025) | Net income (CHF111.7m) (FY, 2025) | Net income $7.7b (FY, 2025) | Net income $8.5b (FY, 2025) | Net income $4.5b (FY, 2025) |
Operating ⚠ | ||||||
Countries | Countries N/A | Countries N/A | Countries N/A | Countries 100 (FY, 2020) | Countries 35 (FY, 2021) | Countries N/A |
Patents (EU) | Patents (EU) N/A | Patents (EU) N/A | Patents (EU) N/A | Patents (EU) 21 (FY, 2020) | Patents (EU) N/A | Patents (EU) 17 (FY, 2020) |
Patents (US) | Patents (US) N/A | Patents (US) N/A | Patents (US) N/A | Patents (US) 31 (FY, 2020) | Patents (US) N/A | Patents (US) 31 (FY, 2020) |
Phase I Trials Products (Oncology) | Phase I Trials Products (Oncology) N/A | Phase I Trials Products (Oncology) 9 (FY, 2021) | Phase I Trials Products (Oncology) N/A | Phase I Trials Products (Oncology) N/A | Phase I Trials Products (Oncology) 7 (FY, 2019) | Phase I Trials Products (Oncology) N/A |
Phase II Trials Products (Oncology) | Phase II Trials Products (Oncology) N/A | Phase II Trials Products (Oncology) 12 (FY, 2021) | Phase II Trials Products (Oncology) N/A | Phase II Trials Products (Oncology) N/A | Phase II Trials Products (Oncology) 1 (FY, 2021) | Phase II Trials Products (Oncology) N/A |
Phase III Trials Products | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products 11 (FY, 2020) | Phase III Trials Products 9 (FY, 2021) | Phase III Trials Products N/A |
Products | Products N/A | Products N/A | Products N/A | Products N/A | Products 21 (FY, 2021) | Products 11 (FY, 2022) |
Projects in R&D Pipeline | Projects in R&D Pipeline N/A | Projects in R&D Pipeline 91 (FY, 2019) | Projects in R&D Pipeline 12 (FY, 2019) | Projects in R&D Pipeline N/A | Projects in R&D Pipeline N/A | Projects in R&D Pipeline N/A |
Funding | ||||||
Total funding raised | Total funding raised N/A | Total funding raised $ 310m | Total funding raised N/A | Total funding raised N/A | Total funding raised N/A | Total funding raised $ 53.9m |
For sources of this data, please see the company profile
View Company Profiles
Sanofi
HQ
Paris, FR
Employees
82,878
Sanofi is a healthcare company engaged in the research, development, manufacture, and marketing of therapeutic solutions.
View companyIdorsia
HQ
Allschwil, CH
Employees
800↑ 7% increase
Idorsia, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs.
View companyAmgen
HQ
Thousand Oaks, US
Employees
25,200
Amgen (formerly known as Applied Molecular Genetics) is a biotechnology company that discovers, develops, manufactures, and delivers human therapeutics.
View companyGilead Sciences
HQ
Foster City, US
Employees
18,000↑ 6% increase
Gilead Sciences is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of medicines.
View company